Verastem, Inc. (VSTM) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$8.58

From 52W high−18.98%

Volume3.39M

Market cap$1.05B

P/E (TTM)—

P/S (TTM)12.0x

Div yield—

Key dataOct 19, 2026

Open

$8.58

From 52W high

−18.98%

Volume

3.39M

Market cap

$1.05B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.0x

P/E (TTM)

—

RSI (14)

59.2

MomentumView details →

1D Return

−0.35%

YTD Return

+14.57%

SummaryUpdated Jun 1, 2026

Verastem, Inc. (NASDAQ:VSTM) is a development-stage biopharmaceutical company founded in 2010 and headquartered in Needham, Massachusetts. The company went public in January 2012 and focuses on developing innovative cancer treatments through targeted therapies. Verastem operates as a clinical-stage biotechnology firm, meaning it does not yet have approved products generating commercial revenue, but instead invests heavily in research and development to advance promising drug candidates through clinical trials toward potential FDA approval.

Ask drillr about Verastem, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.0x

EV/Sales

11.4x

P/S (TTM)

12.0x

P/B (TTM)

20.9x

ProfitabilityView details →

Gross Margin

86.69%

Net Margin

−231.59%

EBITDA Margin

−228.02%

ROE (TTM)

−405.51%

ROA (TTM)

−98.15%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

+3995.74%

EPS YoY

+32.60%

FCF YoY

−36.02%

Revenue CAGR 3Y

+128.36%

EPS CAGR 3Y

+17.49%

EBITDA YoY

−22.05%

MomentumView details →

1D Return

−0.35%

YTD Return

+14.57%

1Y Return

+10.29%

RSI (14)

59.2

vs 50D SMA

+15.53%

vs 200D SMA

+46.02%

Capital & dividendView details →

Debt/Equity

1.69x

Current Ratio

2.25x

Quick Ratio

2.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.35

EPS Surprise

18.70%

Beats (12Q)

4/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

−37.01%

Rev Surprise

75.17%

Financials snapshotView financials →

Revenue (TTM)

87.53M

Net Income (TTM)

−202.70M

Op. CF (TTM)

−162.19M

Next earningsNov 3, 2026 →

Latest newsMore news →

Verastem, Inc. plans to raise $250 million.6d ago

Verastem, Inc. reported clinical trial data showing VS-7375 activity in KRAS G12D-mutated cancers, including a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease, one confirmed.6d ago

Similar companies

Cloudbreak Pharma Inc.02592.HK Maravai LifeSciences Holdings, Inc.MRVI Replimune Group, Inc.REPL Immatics N.V.IMTX NewAmsterdam Pharma Company N.V.NAMSW Vor Biopharma Inc.VOR Find similar companies →

Latest newsMore news →

Verastem, Inc. plans to raise $250 million.6d ago Verastem, Inc. reported clinical trial data showing VS-7375 activity in KRAS G12D-mutated cancers, including a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease, one confirmed.6d ago